Lowenstein Sandler LLP
We are only able to display limited information for this firm. We display more complete information for all of the following firms:
Lowenstein Sandler LLP advises life sciences clients on product commercialization and corporate transactions. The team represents emerging, development-stage, and clinical-stage companies, as well as investors, investment banks, and global pharma, biotech, and medical device businesses. Its work includes product acquisitions and divestitures, strategic collaborations, M&A, private financings, and public offerings. In New Jersey, Michael Lerner chairs the life sciences practice and advises public and private healthcare companies and their investors, while Robert Paradiso chairs the life sciences and chemical patents practice and focuses on patent prosecution, litigation, freedom-to-operate issues, and technology transfer. New York-based James Shehan advises life sciences companies on regulatory and commercial matters relating to product development, compliance, and strategic transactions.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘The entire team did a terrific job guiding us through potential pitfalls and working with opposing counsel in a collaborative way to get the transaction completed. It was probably the most complicated transaction we have worked on, and we were glad to have Lowenstein with us.’
‘This practice combines sophisticated legal and transactional experience with a true understanding of the business and what it's like to build and run a company.’
Key clients
- Crown Laboratories, Inc.
- Goldeneye 1995, LLC
Work highlights
Representing Sonnet BioTherapeutics, Inc. in Agreement to Launch $888M HYPE Cryptocurrency Treasury Reserve Strategy.